PetIQ (PETQ) to Release Earnings on Wednesday

PetIQ (NASDAQ:PETQ) is scheduled to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.42 per share for the quarter. PetIQ has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

PetIQ (NASDAQ:PETQ) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.22. PetIQ had a return on equity of 11.72% and a net margin of 0.19%. The business had revenue of $219.93 million for the quarter, compared to analyst estimates of $189.70 million. On average, analysts expect PetIQ to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

PetIQ Stock Performance

Shares of NASDAQ:PETQ opened at $17.04 on Monday. The stock has a market capitalization of $501.49 million, a price-to-earnings ratio of 284.05 and a beta of 1.68. The business’s fifty day moving average price is $17.10 and its two-hundred day moving average price is $18.01. PetIQ has a fifty-two week low of $11.26 and a fifty-two week high of $22.98. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.27 and a quick ratio of 1.43.

Analyst Ratings Changes

Separately, Jefferies Financial Group increased their target price on shares of PetIQ from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Four equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, PetIQ has a consensus rating of “Buy” and a consensus target price of $29.00.

About PetIQ

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.